


Next Generation Sequencing Market to reach USD 42.61 Billion by 2035 at 14.7% CAGR

Next Generation Sequencing Market to Surge from USD 11.02 Bn in 2025 to USD 42.61 Bn by 2035-By Precision Oncology Reimbursement, Declining Cost Per Genome

NY, CA, UNITED STATES, September 2, 2026 /EINPresswire.com/ -- As per Market Research Future, the [global Next Generation Sequencing Market size](#) is projected to reach USD 42.61 Billion by 2035 from USD 11.02 Billion in 2025, at a CAGR of 14.7% during the forecast period 2026--2035. The market value is expected to reach USD 12.40 Billion in 2026 as the first year of the forecast period.



The 14.7% CAGR---anchored by structural shifts in genomic medicine---is propelled by three converging forces: expanding clinical reimbursement for genomic profiling and large-scale public sequencing initiatives, which have moved comprehensive genomic profiling from research budgets into routine clinical line items; advancements in sequencing instruments, particularly high-output systems and on-cartridge workflows that compress turnaround time from days to hours, with cost per genome falling below the USD 200 threshold on flagship platforms; and the integration of multiomics workflows, including single-cell and spatial transcriptomics, that raise reagent consumption per instrument without requiring new capital purchases.

Global sequencing platform manufacturers and health organizations are amplifying this momentum. Illumina, Inc. holds an estimated 34--40% revenue share, reflecting strong investment in core sequencing platforms and informatics. Thermo Fisher Scientific reports sequencing-linked revenue growth tied to pharma service contracts, supporting its broad life sciences portfolio. According to NHGRI data, per-genome pricing has fallen by orders of magnitude since 2008, far outpacing semiconductor cost curves. The European Union's 1+ Million Genomes initiative and India's GenomeIndia programme have committed public capital to sequencing capacity that private demand alone would not have justified. These forces are

creating the clinical infrastructure and research demand on which the Next Generation Sequencing Market depends.

Request A Free Sample:

https://www.marketresearchfuture.com/sample_request/6354

Key Market Trends & Growth Drivers

Rising Demand for Precision Oncology and Companion Diagnostics

The market is witnessing increasing demand for sequencing-based cancer diagnostics. As precision medicine moves into standard of care, more oncology patients are receiving comprehensive genomic profiling. The Centers for Medicare & Medicaid Services national coverage determination for sequencing-based cancer diagnostics established reimbursement for FDA-approved companion diagnostics in advanced solid tumours, converting a discretionary test into a billable one. Illumina continues advancing its NovaSeq X series and DRAGEN informatics while defending its consumable ecosystem.

Advancements in Sequencing Instruments and Workflows

Innovations in sequencing platforms are becoming a hallmark of the industry. Laboratories are retiring mid-life benchtop platforms in favor of high-output systems and on-cartridge workflows that compress turnaround time from days to hours. These advancements aim to enhance throughput and convenience, potentially leading to better diagnostic outcomes and increased market penetration. High-output instrument fleets are turning over faster than at any point since short-read chemistry displaced capillary electrophoresis.

Integration of Multiomics and Spatial Workflows

The incorporation of multiomics technologies into sequencing workflows is gaining traction. Single-cell transcriptomics, spatial profiling, and proteogenomic workflows run on installed sequencers, raising utilisation without new capital. 10x Genomics continues investing in single-cell and spatial workflow solutions that ride the installed sequencer base, generating significant application-layer revenue.

Increasing Prevalence of Genomic Screening and Rare Disease Testing

The rising adoption of newborn and carrier screening is a primary driver. Genomics England's Generation Study began sequencing newborns at population scale in late 2024, establishing the largest clinical newborn sequencing cohort to date. The market is projected to expand as healthcare providers increasingly prescribe whole exome sequencing to manage diagnostic odysseys for rare disease. Whole exome sequencing is advancing at a 15.2% CAGR, the fastest

among sequencing types.

Sovereign Genomics Programmes Anchor Baseline Demand

Public commitments have created a demand floor insulated from research funding cycles. The European Union's 1+ Million Genomes initiative brought together participating member states around cross-border genomic data access, while India's GenomeIndia project completed reference sequencing across thousands of individuals spanning the country's population groups. Procurement under these programmes runs on multi-year frameworks, giving suppliers revenue visibility that commercial channels rarely offer.

Ask for Customization:

https://www.marketresearchfuture.com/ask_for_customize/6354

Market Segment Insights

BY TYPE OF SEQUENCING

Targeted Resequencing: Largest segment with 35.4% share in 2025, driven by oncology panel volumes in hospital pathology labs. Illumina continues expanding targeted sequencing through sustained product innovation.

Whole Exome Sequencing: Fastest-growing segment at 15.2% CAGR, appealing to diagnostic pathways for undiagnosed paediatric disease.

Whole Genome Sequencing: Positioned as a significant entry catering to population cohorts and rare disease diagnosis, valued at USD 2.71 Billion in 2025.

Methyl Sequencing: Fastest-growing novel segment at 14.9% CAGR, driven by early cancer detection assay development.

BY PRODUCT TYPE

Reagents and Consumables: Largest segment with 65.0% share in 2025, benefiting from recurring run volume across installed fleets. Illumina continues strengthening consumable revenue through ecosystem expansion.

Instruments: Fastest-growing segment at 15.4% CAGR, due to fleet replacement and benchtop decentralisation.

Services: Significant share at USD 1.34 Billion in 2025, driven by outsourced sequencing for biopharma and biobanks.

BY APPLICATION

Drug Discovery and Personalized Medicine: Largest segment with USD 3.61 Billion in 2025, due to high demand in target identification and patient stratification.

Genetic Screening: Fastest-growing application at 15.3% CAGR, as population screening programmes expand and per-test economics clear reimbursement thresholds.

Diagnostics: Significant share at 24.1% in 2025, reflecting reimbursed oncology and infectious disease testing.

Reproductive Health: Fastest-growing emerging application at 14.4% CAGR, positioning itself for non-invasive prenatal testing expansion.

BY END USER

Academic Institutes: Largest segment with 45.1% share in 2025, offering robust research funding and core facility capacity.

Hospitals and Healthcare Institutions: Fastest-growing end user at 15.6% CAGR, positioning itself as clinical laboratories bring testing in-house rather than sending specimens to reference providers.

Pharmaceutical and Biotechnology Companies: Significant share at USD 3.04 Billion in 2025, driven by translational research and companion diagnostics.

Read Detailed Insights:

<https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354>

Regional Outlook

North America --- Market Leader in Innovation

North America leads with 38.9% of global revenue in 2025, generating around USD 4.29 Billion. The region's growth is driven by deep clinical reimbursement, a dense academic core-lab base, and favorable CMS coverage for genomic profiling in advanced cancers. According to CDC estimates, the United States dominates through payer infrastructure rather than instrument density alone. The competitive landscape is characterized by continuous innovation and strategic partnerships among leading sequencing platform manufacturers.

Europe --- Second Largest Market

Europe was valued at USD 3.02 billion in 2025, representing the second-largest regional market. The region benefits from IVDR compliance consolidating demand toward validated platforms and supportive sovereign programmes such as Genomics England's Generation Study. Regulatory bodies like the EMA are actively facilitating the approval of new in vitro diagnostics. Leading countries include Germany, the UK, and France, where major sequencing initiatives are heavily invested.

Asia-Pacific --- Rapidly Growing Market Segment

The Asia-Pacific region is set to register a 15.2% CAGR from 2026 to 2035, the fastest-growing region. The growth is driven by domestic instrument manufacturing, national cohorts, and increasing healthcare access. Countries like China and India are experiencing a surge in demand, supported by government initiatives such as the GenomeIndia programme and China's domestic DNBSAQ platforms. The competitive landscape is evolving with companies like BGI Genomics / MGI Tech leading the charge.

South America --- Emerging Opportunity

South America was valued at USD 0.51 Billion in 2025, driven by public health labs and oncology access expansion. Brazil anchors regional demand through a two-tier structure of public system oncology testing and private laboratory networks.

Middle East and Africa --- Untapped Potential

The MEA region holds around 3.3% of the global share, driven by sovereign genome programmes and consanguinity screening. Countries like Saudi Arabia and the UAE are leading the way, with a growing presence of international and domestic sequencing capacity.

Competitive Landscape and Recent Developments

The Next Generation Sequencing market is characterized by intense competition and rapid growth, driven by increasing clinical adoption of genomic testing worldwide. The global industry appears moderately concentrated with an HHI near 1,650, with several key players exerting significant influence.

KEY COMPANIES AND RECENT MILESTONES

Illumina, Inc. (US): Holds an estimated 34--40% revenue share. Completed the separation of GRAIL as an independent public company in June 2024, refocusing capital on core sequencing platforms and informatics.

Thermo Fisher Scientific (US): Holds an estimated 10--13% revenue share. Closed its acquisition

of Olink in July 2024, extending multiomics capability adjacent to sequencing workflows and deepening pharma research relationships.

BGI Genomics / MGI Tech (CN): Holds an estimated 7--10% revenue share. Introduced ultra-high-throughput DNBSEQ systems positioned for national cohort programmes, intensifying cost-per-gigabase competition outside Western markets.

Roche (CH): Holds an estimated 5--8% revenue share. Unveiled its sequencing-by-expansion chemistry in February 2025, signalling a credible new entrant into the platform tier for the first time in over a decade.

Other Key Players: QIAGEN N.V. (NL), Oxford Nanopore Technologies (GB), Pacific Biosciences (US), Agilent Technologies (US), Element Biosciences (US), Ultima Genomics (US), 10x Genomics (US), Eurofins Genomics (LU).

Future Outlook: 2026--2035

The Next Generation Sequencing Market is projected to reach USD 42.61 billion by 2035, growing at a CAGR of 14.7%, driven by precision oncology adoption, sovereign genomics programmes, and declining sequencing costs.

New opportunities lie in:

Expansion into emerging markets with bundled installation, informatics, and workforce development

Development of open-chemistry systems to break proprietary consumable lock-in

Investment in machine learning-based variant interpretation to relieve workforce constraints

Integration of sustainability reporting into procurement scoring

By 2035, the Next Generation Sequencing Market is expected to achieve substantial growth and innovation.

More Related Research Insights:

<https://www.marketresearchfuture.com/fr/reports/cosmetic-surgery-market-3157>

<https://www.marketresearchfuture.com/fr/reports/dental-prosthetics-market-2905>

<https://www.marketresearchfuture.com/fr/reports/diabetes-drug-market-1160>

<https://www.marketresearchfuture.com/fr/reports/diabetic-nephropathy-market-5664>

<https://www.marketresearchfuture.com/fr/reports/dry-eye-syndrome-market-5588>

<https://www.marketresearchfuture.com/fr/reports/emergency-medical-services-market-8363>

<https://www.marketresearchfuture.com/ja/reports/acupuncture-market-6139>

<https://www.marketresearchfuture.com/ja/reports/ai-drug-discovery-market-9393>

<https://www.marketresearchfuture.com/ja/reports/animal-stem-cell-therapy-market-35924>

<https://www.marketresearchfuture.com/ja/reports/anti-ageing-drugs-market-3504>

Market Research Future

Market Research Future

+1 855-661-4441

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/939007061>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.